A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe,
tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and
atazanavir administered once daily. Over the course of 48 weeks, various parameters that
measure safety, tolerability and efficacy of the investigational drugs were measured and
compared.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Atazanavir Sulfate Lamivudine, zidovudine drug combination